Credit Suisse Ag Neurocrine Biosciences Inc Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Credit Suisse Ag holds 169,161 shares of NBIX stock, worth $20.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

169,161

Previous 200,181 15.5%

Holding current value

$20.4 Million

Previous $26.4 Million 11.55%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$130.4 - $143.74 $4.05 Million - $4.46 Million	-31,020 Reduced 15.5%	169,161 $23.3 Million
Q4 2023 Feb 08, 2024	SELL	$106.07 - $132.76 $3.46 Million - $4.34 Million	-32,664 Reduced 14.03%	200,181 $26.4 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $718,218 - $894,526	-7,639 Reduced 3.18%	232,845 $26.2 Million
Q2 2023 Aug 11, 2023	SELL	$89.53 - $104.87 $2.23 Million - $2.62 Million	-24,944 Reduced 9.4%	240,484 $22.7 Million
Q1 2023 May 10, 2023	BUY	$94.11 - $123.02 $5.51 Million - $7.2 Million	58,512 Added 28.28%	265,428 $26.9 Million
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $11,098 - $13,214	-104 Reduced 0.05%	206,916 $24.7 Million
Q3 2022 Nov 10, 2022	BUY	$92.03 - $107.81 $3.64 Million - $4.27 Million	39,561 Added 23.62%	207,020 $22 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $235,631 - $311,117	-3,109 Reduced 1.82%	167,459 $16.3 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $755,870 - $989,152	-10,433 Reduced 5.76%	170,568 $16 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $3.31 Million - $4.42 Million	41,585 Added 29.83%	181,001 $15.4 Million
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $1.1 Million - $1.26 Million	12,715 Added 10.04%	139,416 $13.4 Million
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $1.55 Million - $1.77 Million	17,305 Added 15.82%	126,701 $12.3 Million
Q1 2021 May 14, 2021	BUY	$87.57 - $119.4 $79,425 - $108,295	907 Added 0.84%	109,396 $10.6 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $55,622 - $69,331	-640 Reduced 0.59%	108,489 $10.4 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $123,180 - $173,127	1,281 Added 1.19%	109,129 $10.5 Million
Q2 2020 Aug 12, 2020	BUY	$85.09 - $130.36 $337,977 - $517,789	3,972 Added 3.82%	107,848 $13.2 Million
Q1 2020 May 13, 2020	SELL	$75.11 - $113.76 $2.63 Million - $3.98 Million	-34,961 Reduced 25.18%	103,876 $8.99 Million
Q4 2019 Feb 12, 2020	BUY	$86.8 - $118.57 $1.71 Million - $2.34 Million	19,747 Added 16.58%	138,837 $14.9 Million
Q3 2019 Nov 12, 2019	BUY	$83.82 - $101.5 $3.8 Million - $4.6 Million	45,344 Added 61.49%	119,090 $10.7 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $129,887 - $164,103	-1,798 Reduced 2.38%	73,746 $6.23 Million
Q1 2019 May 14, 2019	SELL	$69.31 - $91.53 $23.6 Million - $31.2 Million	-340,815 Reduced 81.86%	75,544 $6.66 Million
Q4 2018 Feb 13, 2019	BUY	$68.32 - $124.36 $6.87 Million - $12.5 Million	100,569 Added 31.85%	416,359 $29.7 Million
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $2.94 Million - $3.74 Million	29,742 Added 10.4%	315,790 $38.8 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $12.9 Million - $18.2 Million	-171,321 Reduced 37.46%	286,048 $28.1 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $9.94 Million - $12.1 Million	130,933 Added 40.11%	457,369 $37.9 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $5.23 Million - $6.93 Million	89,320 Added 37.67%	326,436 $25.3 Million
Q3 2017 Nov 14, 2017	SELL	$47.97 - $61.28 $960,839 - $1.23 Million	-20,030 Reduced 7.79%	237,116 $14.5 Million
Q2 2017 Aug 14, 2017	BUY	N/A	257,146	257,146 $11.8 Million

Others Institutions Holding NBIX

# of Institutions

654

Shares Held

96.5M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account